Logo image of AEZS

AETERNA ZENTARIS INC (AEZS) Stock Fundamental Analysis

NASDAQ:AEZS - Nasdaq - CA0079756007 - Common Stock - Currency: USD

5.72  +0.32 (+5.93%)

Fundamental Rating

1

Taking everything into account, AEZS scores 1 out of 10 in our fundamental rating. AEZS was compared to 566 industry peers in the Biotechnology industry. Both the profitability and financial health of AEZS have multiple concerns. AEZS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AEZS has reported negative net income.
In the past year AEZS has reported a negative cash flow from operations.
AEZS had negative earnings in each of the past 5 years.
AEZS had a negative operating cash flow in each of the past 5 years.
AEZS Yearly Net Income VS EBIT VS OCF VS FCFAEZS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of AEZS (-56.80%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -139.22%, AEZS is doing worse than 62.76% of the companies in the same industry.
Industry RankSector Rank
ROA -56.8%
ROE -139.22%
ROIC N/A
ROA(3y)-31.91%
ROA(5y)-27.9%
ROE(3y)-56.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AEZS Yearly ROA, ROE, ROICAEZS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 -400

1.3 Margins

With an excellent Gross Margin value of 90.69%, AEZS belongs to the best of the industry, outperforming 93.18% of the companies in the same industry.
In the last couple of years the Gross Margin of AEZS has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for AEZS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y39.35%
GM growth 5Y0.62%
AEZS Yearly Profit, Operating, Gross MarginsAEZS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

3

2. Health

2.1 Basic Checks

AEZS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AEZS has less shares outstanding
AEZS has more shares outstanding than it did 5 years ago.
AEZS has a worse debt/assets ratio than last year.
AEZS Yearly Shares OutstandingAEZS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
AEZS Yearly Total Debt VS Total AssetsAEZS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -16.76, we must say that AEZS is in the distress zone and has some risk of bankruptcy.
AEZS's Altman-Z score of -16.76 is on the low side compared to the rest of the industry. AEZS is outperformed by 85.49% of its industry peers.
AEZS has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
AEZS has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: AEZS outperforms 48.08% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -16.76
ROIC/WACCN/A
WACC10.12%
AEZS Yearly LT Debt VS Equity VS FCFAEZS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 5.94 indicates that AEZS has no problem at all paying its short term obligations.
AEZS has a Current ratio of 5.94. This is comparable to the rest of the industry: AEZS outperforms 59.09% of its industry peers.
AEZS has a Quick Ratio of 5.93. This indicates that AEZS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of AEZS (5.93) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.94
Quick Ratio 5.93
AEZS Yearly Current Assets VS Current LiabilitesAEZS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for AEZS have decreased strongly by -274.15% in the last year.
AEZS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -62.06%.
Measured over the past years, AEZS shows a very negative growth in Revenue. The Revenue has been decreasing by -30.07% on average per year.
EPS 1Y (TTM)-274.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-438.43%
Revenue 1Y (TTM)-62.06%
Revenue growth 3Y6.73%
Revenue growth 5Y-30.07%
Sales Q2Q%-99.81%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y68.75%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-2.27%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AEZS Yearly Revenue VS EstimatesAEZS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
AEZS Yearly EPS VS EstimatesAEZS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AEZS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AEZS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AEZS Price Earnings VS Forward Price EarningsAEZS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AEZS Per share dataAEZS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AEZS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AETERNA ZENTARIS INC

NASDAQ:AEZS (8/8/2024, 8:00:00 PM)

5.72

+0.32 (+5.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2024-08-08/bmo
Earnings (Next)11-07 2024-11-07/bmo
Inst Owners0.81%
Inst Owner Change11.72%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap17.51M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.37
P/FCF N/A
P/OCF N/A
P/B 1.35
P/tB 1.35
EV/EBITDA N/A
EPS(TTM)-11
EYN/A
EPS(NY)-3.44
Fwd EYN/A
FCF(TTM)-5.67
FCFYN/A
OCF(TTM)-5.67
OCFYN/A
SpS0.78
BVpS4.24
TBVpS4.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.8%
ROE -139.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.69%
FCFM N/A
ROA(3y)-31.91%
ROA(5y)-27.9%
ROE(3y)-56.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y39.35%
GM growth 5Y0.62%
F-Score1
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.87%
Cap/Sales 1.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.94
Quick Ratio 5.93
Altman-Z -16.76
F-Score1
WACC10.12%
ROIC/WACCN/A
Cap/Depr(3y)148.35%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.23%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-274.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-438.43%
EPS Next Y68.75%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-62.06%
Revenue growth 3Y6.73%
Revenue growth 5Y-30.07%
Sales Q2Q%-99.81%
Revenue Next Year-2.27%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-90.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-92.97%
OCF growth 3YN/A
OCF growth 5YN/A